920
Views
0
CrossRef citations to date
0
Altmetric
Other

Assessing the applicability of obstetrical randomized controlled trials in real-world practices

ORCID Icon &
Article: 2325580 | Received 31 Jan 2024, Accepted 26 Feb 2024, Published online: 03 Mar 2024

References

  • Nelson DB, McIntire DD, Leveno KJ. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth. Am J Obstet Gynecol. 2021;224(2):1–6. doi: 10.1016/j.ajog.2020.09.045.
  • McGoldrick E, Stewart F, Parker R, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12(12):CD004454. doi: 10.1002/14651858.CD004454.pub4.
  • Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD001058. doi: 10.1002/14651858.CD001058.pub2.
  • Tita AT, Szychowski JM, Boggess K, et al. Chronic hypertension and pregnancy (CHAP) trial consortium. N Engl J Med. 2022;386(19):1781–1792. doi: 10.1056/NEJMoa2201295.
  • ACOG Practice Advisory. Clinical guidance for the integration of the findings of the Chronic Hypertension and Pregnancy (CHAP) study. 2022 Apr [cited 2023 Dec 27]. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/04/clinical-guidance-for-the-integration-of-the-findings-of-the-chronic-hypertension-and-pregnancy-chap-study
  • Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18–31. doi: 10.1002/uog.9017.
  • Owen J, Hankins G, Iams JD, et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol. 2009;201(4):375.e1–375.e8. doi: 10.1016/j.ajog.2009.08.015.
  • Ewigman BG, Crane JP, Frigoletto FD, et al. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS study group. N Engl J Med. 1993;329(12):821–827. doi: 10.1056/NEJM199309163291201.
  • LeFevre ML, Bain RP, Ewigman BG, et al. A randomized trial of prenatal ultrasonographic screening: impact on maternal management and outcome. RADIUS (routine antenatal diagnostic imaging with ultrasound) study group. Am J Obstet Gynecol. 1993;169(3):483–489. doi: 10.1016/0002-9378(93)90605-i.
  • Romero R. Routine obstetric ultrasound. Ultrasound Obstet Gynecol. 1993;3(5):303–307. doi: 10.1046/j.1469-0705.1993.03050303.x.
  • Larion S, Warsof SL, Romary L, et al. Use of the combined first-trimester screen in high- and low-risk patient populations after introduction of noninvasive prenatal testing. J Ultrasound Med. 2015;34(8):1423–1428. doi: 10.7863/ultra.34.8.1423.
  • Liao Y, Wen H, Ouyang S, et al. Routine first-trimester ultrasound screening using a standardized anatomic protocol. Am J Obstet Gynecol. 2021;224(4):396.e1–396.e15. doi: 10.1016/j.ajog.2020.10.037.
  • Abramowicz JS. Obstetric ultrasound: where are we and where are we going? Ultrasonography. 2021;40(1):57–74. doi: 10.14366/usg.20088.
  • Haverkamp AD, Thompson HE, McFee JG, et al. The evaluation of continuous fetal heart rate monitoring in high-risk pregnancy. Am J Obstet Gynecol. 1976;125(3):310–320. doi: 10.1016/0002-9378(76)90565-2.
  • Haverkamp AD, Orleans M, Langendoerfer S, et al. A controlled trial of the differential effects of intrapartum fetal monitoring. Am J Obstet Gynecol. 1979;134(4):399–412. doi: 10.1016/s0002-9378(16)33082-4.
  • Renou P, Chang A, Anderson I, et al. Controlled trial of fetal intensive care. Am J Obstet Gynecol. 1976;126(4):470–476. doi: 10.1016/0002-9378(76)90641-4.
  • Kelso IM, Parsons RJ, Lawrence GF, et al. An assessment of continuous fetal heart rate monitoring in labor. A randomized trial. Am J Obstet Gynecol. 1978;131(5):526–532. doi: 10.1016/0002-9378(78)90114-x.
  • Wood C, Renou P, Oats J, et al. A controlled trial of fetal heart rate monitoring in a low-risk obstetric population. Am J Obstet Gynecol. 1981;141(5):527–534. doi: 10.1016/s0002-9378(15)33273-7.
  • MacDonald D, Grant A, Sheridan-Pereira M, et al. The Dublin randomized controlled trial of intrapartum fetal heart rate monitoring. Am J Obstet Gynecol. 1985;152(5):524–539. doi: 10.1016/0002-9378(85)90619-2.
  • Neldam S, Osler M, Hansen PK, et al. Intrapartum fetal heart rate monitoring in a combined low- and high-risk population: a controlled clinical trial. Eur J Obstet Gynecol Reprod Biol. 1986;23(1-2):1–11. doi: 10.1016/0028-2243(86)90099-7.
  • Luthy DA, Shy van Belle G, Larson EB, et al. A randomized trial of electronic fetal monitoring in preterm labor. Obstet Gynecol. 1987;69(5):687–695.
  • Chen H-Y, Chauhan SP, Ananth CVHY, et al. Electronic fetal heart rate monitoring and its relationship to neonatal and infant mortality in the United States. Am J Obstet Gynecol. 2011;204(6):491.e1–491.10. doi: 10.1016/j.ajog.2011.04.024.
  • Smith V, Begley C, Newell J, et al. Admission cardiotocography versus intermittent auscultation of the fetal heart in low-risk pregnancy during evaluation for possible labour admission-a multicentre randomised trial: the ADCAR trial. BJOG. 2019;126(1):114–121. doi: 10.1111/1471-0528.15448.
  • Vintzileos AM. Intrapartum cardiotocography has become the standard of care even in low-risk pregnancies. BJOG. 2019;126(1):122–122. doi: 10.1111/1471-0528.15445.
  • Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379–2385. doi: 10.1056/NEJMoa035140.
  • Blackwell SC, Gyamfi-Bannerman C, Biggio JR, et al. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized Double-Blind trial. Am J Perinatol. 2020;37(2):127–136. doi: 10.1055/s-0039-3400227.
  • U.S. Food and Drug Administration. FDA commissioner and chief scientist announce decision to withdraw approval of Makena. FDA; 2023 [cited 2023 Apr 6]. Available from: https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena
  • Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107(1):91–96. doi: 10.1097/01.AOG.0000192404.25780.68.
  • Berkowitz RL, Lesser M, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia. Obstet Gynecol. 2007;110(2 Pt 1):249–255. doi: 10.1097/01.AOG.0000270302.80336.dd.
  • Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol. 1995;172(2 Pt 1):475–479. doi: 10.1016/0002-9378(95)90559-6.
  • Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993–­1004. doi: 10.1056/NEJMoa1014379.
  • Johnson MP, Bennett KA, Rand L, et al. The management of myelomeningocele study: obstetrical outcomes and risk factors for obstetrical complications following prenatal surgery. Am J Obstet Gynecol. 2016;215(6):778.e1–778.e9. doi: 10.1016/j.ajog.2016.07.052.
  • Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217–224. doi: 10.31887/DCNS.2011.13.2/npatsopoulos.